Zacks Research Predicts Increased Earnings for Exelixis

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research upped their FY2027 earnings per share (EPS) estimates for Exelixis in a research note issued on Thursday, September 3rd. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $3.59 for the year, up from their prior forecast of $3.57. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis’ Q1 2028 earnings at $0.97 EPS.

Other analysts have also recently issued research reports about the stock. Leerink Partners cut shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price for the company. in a research note on Thursday, August 6th. Morgan Stanley upped their price target on shares of Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 23rd. UBS Group set a $55.00 price target on shares of Exelixis in a report on Monday, August 3rd. Wall Street Zen downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and set a $56.00 target price on shares of Exelixis in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $50.07.

Exelixis Price Performance

Exelixis stock opened at $59.01 on Monday. The business has a 50 day simple moving average of $55.16 and a 200-day simple moving average of $49.65. Exelixis has a 12 month low of $33.76 and a 12 month high of $59.72. The stock has a market capitalization of $14.62 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 1.76 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. During the same period last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis.

Insider Activity at Exelixis

In other news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Exelixis

Institutional investors have recently made changes to their positions in the stock. Motiv8 Investments LLC purchased a new stake in Exelixis during the 4th quarter worth about $26,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Exelixis during the 1st quarter worth about $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Exelixis during the fourth quarter worth about $29,000. Western Wealth Management LLC purchased a new stake in shares of Exelixis during the first quarter worth about $29,000. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 773 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.